Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of British Columbia

$573,752.00

Understanding the immune response to the oncomicrobe Fusobacterium nucleaum

FY 2025-26

Summary
Fusobacterium nucleatum (Fn) is a common oral bacterium that can travel through the bloodstream and cause or worsen diseases, including certain cancers, at other body sites. In people with colon cancer, high levels of Fn in tumours are linked to faster disease progression, resistance to treatment, and poorer survival. While antibiotics like metronidazole can treat Fn, long-term use is problematic, so vaccination may be a better option for people at risk. Our research has shown that a whole-cell Fn vaccine can reduce tumour infection in mice, but we still need to understand which parts of the immune system are most important for controlling Fn. In this project, we will study immune responses to Fn in both cancer patients and healthy people, and test the roles of different immune cells and antibodies in protecting against Fn in mouse models. We will also test specific Fn proteins that trigger protective immune responses, with the ultimate goal of developing a safe and effective vaccine to help patients at risk for Fn-related colorectal cancer.
Program
Project Grant
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
565620
Name
Holt Rob
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Understanding the immune response to the oncomicrobe Fusobacterium nucleaum
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$573,752
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Antibodies; Colorectal Cancer; Fusobacterium Nucleatum; Microbiome; Oncomicrobe; Proteomics; Serology; T Cells; Tumour Progression; Vaccine
Abstract
Fusobacterium nucleatum (Fn) is a common oral bacterium that can travel through the bloodstream and cause or worsen diseases, including certain cancers, at other body sites. In people with colon cancer, high levels of Fn in tumours are linked to faster disease progression, resistance to treatment, and poorer survival. While antibiotics like metronidazole can treat Fn, long-term use is problematic, so vaccination may be a better option for people at risk. Our research has shown that a whole-cell Fn vaccine can reduce tumour infection in mice, but we still need to understand which parts of the immune system are most important for controlling Fn. In this project, we will study immune responses to Fn in both cancer patients and healthy people, and test the roles of different immune cells and antibodies in protecting against Fn in mouse models. We will also test specific Fn proteins that trigger protective immune responses, with the ultimate goal of developing a safe and effective vaccine to help patients at risk for Fn-related colorectal cancer.
Competitiondate
202603
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Holt, Rob
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $573,752~ $0~
University of British Columbia - $573,752 Grant (2025… | Canada Spends